# US 2013/0158000 A1 · Disubstituted benzothienyl-pyrrolotriazines and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158000 A1
- Document ID: US20130158000A1
- Status: Published application
- Kind: A1
- Application number: 13/715,553
- Filed: 2012-12-14
- Published: 2013-06-20
- Earliest claimed: 2011-12-15
- Assignees: Bayer Intellectual Property GmbH
- Inventors: Dirk BROHM; Melanie HEROULT; Marie-Pierre COLLIN; Walter HÜBSCH; Mario LOBELL; Klemens LUSTIG; Sylvia GRÜNEWALD; Ulf BÖMER
- Web page: https://patentgrep.com/patent/US20130158000A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 is hydrogen, chloro, methyl or methoxy,
R2 is hydrogen or methoxy,
with the proviso that at least one of R1 and R2 is other than hydrogen,
G1 represents chloro, (C1-C4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group —CH2—OR3, —CH2—NR4R5 or —C(═O)—NR4R6, wherein
R3 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or phenyl,
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy, (C1-C4)-alkoxy, hydroxycarbonyl, (C1-C4)-alkoxycarbonyl, amino, aminocarbonyl, mono(C1-C4)-alkylaminocarbonyl, di-(C1-C4)-alkylaminocarbonyl, (C3-C6)-cycloalkyl or up to three fluoro atoms,
and
(ii) said (C3-C6)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy and amino,
and
(iii) said phenyl is optionally substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, trifluoromethoxy, (C1-C4)-alkyl and (C1-C4)-alkoxy,
R4 is hydrogen or (C1-C4)-alkyl,
R5 is hydrogen, (C1-C4)-alkyl, (C1-C4)-alkylcarbonyl, (C3-C6)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy, (C1-C4)-alkoxy, hydroxycarbonyl, (C1-C4)-alkoxycarbonyl, aminocarbonyl, mono-(C1-C4)alkylaminocarbonyl, di-(C1-C4)-alkylaminocarbonyl or (C3-C6)-cycloalkyl,
and
(ii) said (C3-C6)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy and amino,
and
(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy, oxo and amino,
R6 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy, (C1-C4)-alkoxy, hydroxycarbonyl, (C1-C4)-alkoxycarbonyl, amino, aminocarbonyl, mono(C1-C4)-alkylaminocarbonyl, di-(C1-C4)-alkylaminocarbonyl or (C3-C6)cycloalkyl,
and
(ii) said (C3-C6)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy and amino,
and
(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy, oxo and amino,
or
R4 and R5, or R4 and R6, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R7) and O, and which may be substituted on ring carbon atoms with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein
R7 is hydrogen, (C1-C4)-alkyl, formyl or (C1-C4)-alkylcarbonyl,
and
G2 represents chloro, cyano, (C1-C4)-alkyl, or the group —CR8AR8B—OH, —CH2—NR9R10, —C(═O)—NR11R12 or —CH2—OR15, wherein
R8A and R8B are independently selected from the group consisting of hydrogen, (C1-C4)alkyl, cyclopropyl and cyclobutyl,
R9 is hydrogen or (C1-C4)-alkyl,
R10 is hydrogen, (C1-C4)-alkyl, (C1-C4)-alkylcarbonyl, (C3-C6)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C1-C4)-alkylaminocarbonyl or di-(C1-C4)-alkylaminocarbonyl,
and
(ii) said (C3-C6)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy and amino,
and
(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy, oxo and amino,
R11 is hydrogen or (C1-C4)-alkyl,
R12 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C1-C4)-alkylaminocarbonyl or di-(C1-C4)-alkylaminocarbonyl,
and
(ii) said (C3-C6)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy and amino,
and
(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4)-alkyl, hydroxy, oxo and amino,
or
R9 and R10, or R11 and R12, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R13), O, S and S(O)2, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, oxo, hydroxy, amino and aminocarbonyl, and wherein
R13 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, formyl or (C1-C4)-alkylcarbonyl,
and
R15 is (C1-C4)-alkyl,
with the proviso that G1 is not chloro when G2 is chloro or cyano,
or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 2 (depends on 1)

The compound of formula (I) according to claim 1, wherein
R1 is chloro, methyl or methoxy,
R2 is hydrogen or methoxy,
G1 represents chloro, (C1-C4)-alkoxycarbonyl or 5-membered aza-heteroaryl selected from the group consisting of pyrazolyl, imidazolyl, oxazolyl, isoxazolyl and oxadiazolyl, or represents the group —CH2—OR3 or —CH2—NR4R5, wherein
R3 is hydrogen, (C1-C4)-alkyl or (C3-C6)-cycloalkyl,
wherein said (C1-C4)-alkyl is optionally substituted with hydroxy, (C1-C4)alkoxy, hydroxycarbonyl, (C1-C4)-alkoxycarbonyl, amino, aminocarbonyl, (C3-C6)-cycloalkyl or up to three fluoro atoms,
R4 is hydrogen or (C1-C4)-alkyl,
R5 is hydrogen, (C1-C4)-alkyl, (C1-C4)-alkylcarbonyl, (C3-C6)-cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy, hydroxycarbonyl or (C3-C6)-cycloalkyl,
and
(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,
or
R4 and R5 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R7) and O, and which may be substituted on a ring carbon atom with oxo or hydroxy, and wherein
R7 is hydrogen or (C1-C4)-alkyl,
and
G2 represents chloro, cyano, (C1-C4)-alkyl, or the group —CR8AR8B—OH, —CH2—NR9R10, —C(═O)—NR11R12 or —CH2—OR15, wherein
R8A and R8B are independently selected from the group consisting of hydrogen, (C1-C4)alkyl and cyclopropyl,
R9 is hydrogen or methyl,
R10 is hydrogen, (C1-C4)-alkyl, (C1-C4)-alkylcarbonyl, (C3-C6)-cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy or aminocarbonyl,
and
(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,
R11 is hydrogen or methyl,
R12 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein
(i) said (C1-C4)-alkyl is optionally substituted with hydroxy,
and
(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,
or
R9 and R10, or R11 and R12, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R13), O, S and S(O)2, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, oxo, hydroxy, amino and aminocarbonyl, and wherein
R13 is hydrogen, (C1-C4)-alkyl, cyclopropyl, cyclobutyl, formyl or (C1-C4)alkylcarbonyl,
and
R15 is methyl or ethyl,
with the proviso that G1 is not chloro when G2 is chloro or cyano,
or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 3 (depends on 1)

The compound of formula (I) according to claim 1, wherein
R1 is methyl,
R2 is methoxy,
G1 represents methyl, oxazol-5-yl or the group —CH2—OR3 or —CH2—NR4R5, wherein
R3 is hydrogen, (C1-C4)-alkyl, cyclopropyl or cyclobutyl,
wherein said (C1-C4)-alkyl is optionally substituted with hydroxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, amino, amino carbonyl, cyclopropyl, cyclobutyl or up to three fluoro atoms,
R4 is hydrogen, methyl or ethyl,
R5 is hydrogen, (C1-C4)-alkyl, acetyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,
wherein said (C1-C4)-alkyl is optionally substituted with hydroxy, hydroxycarbonyl, cyclopropyl or cyclobutyl,
or
R4 and R5 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 5- or 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from NH and O, and which may be substituted on a ring carbon atom with oxo or hydroxy,
and
G2 represents methyl or the group —CR8AR8B—OH, —CH2—NR9R10 or —C(═O)—NR11R12, wherein
R8A and R8B are independently hydrogen or methyl,
R9 is hydrogen,
R10 is hydrogen, (C1-C4)-alkyl, acetyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,
wherein said (C1-C4)-alkyl is optionally substituted with hydroxy or aminocarbonyl,
R11 is hydrogen or methyl,
R12 is hydrogen, (C1-C4)-alkyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,
wherein said (C1-C4)-alkyl is optionally substituted with hydroxy,
or
R9 and R10, or R11 and R12, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring hetero atom selected from N(R13), O and S(O)2, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, methyl, oxo, hydroxy, amino and aminocarbonyl, and wherein
R13 is hydrogen, formyl or acetyl,
or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 4 (depends on 1)

The compound of formula (I) according to claim 1, wherein
R1 is methyl,
R2 is methoxy,
G1 represents the group —CH2—OR3, wherein
R3 is (C1-C4)-alkyl optionally substituted with hydroxy, amino or aminocarbonyl,
and
G2 represents the group —CH2—NR9R10 or —C(═O)—NR11R12, wherein
R9 is hydrogen,
R10 is 2-oxopyrrolidin-3-yl,
or
R9 and R10 are joined and, taken together with the nitrogen atom to which they are attached, form a piperazin-1-yl, 3-oxopiperazin-1-yl or 4-acetylpiperazin-1-yl ring,
R11 is hydrogen,
R12 is 2-oxopyrrolidin-3-yl,
or
R11 and R12 are joined and, taken together with the nitrogen atom to which they are attached, form a 3-hydroxyazetidin-1-yl, 4-hydroxypiperidin-1-yl or 3-oxopiperazin-1-yl ring,
or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 5 (depends on 1)

A process for preparing a compound of formula (I) according to claim 1, wherein
[A] a 6-substituted 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)
wherein R3 has the meaning indicated in claim 1,
is at first reacted with formaldehyde and an amine of formula (III)
wherein R9 and R10 have the meanings indicated in claim 1,
in the presence of an acid to give a compound of formula (IV)
wherein R3, R9 and R10 have the meanings indicated in claim 1,
then brominated to a compound of formula (V)
wherein R3, R9 and R10 have the meanings indicated in claim 1,
and subsequently coupled with a benzothiophen-2-yl boronate of formula (VI)
wherein R1 and R2 have the meanings indicated in claim 1,
and
R14 represents hydrogen or (C1-C4)-alkyl, or both R14 residues are linked together to form a —(CH2)2—, —C(CH3)2—C(CH3)2—, —(CH2)3—, —CH2—C(CH3)2—CH2— or —C(═O)—CH2—N(CH3)—CH2—C(═O)— bridge,
in the presence of a palladium catalyst and a base to yield the target compound of formula (I-A)
wherein R1, R2, R3, R9 and R10 have the meanings indicated in claim 1,
or
[B] a 6-substituted 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)
wherein R3 has the meaning indicated in claim 1
is at first formylated with N,N-dimethylformamide in the presence of phosphoryl chloride to an aldehyde of formula (VII)
wherein R3 has the meaning indicated in claim 1,
then brominated to a compound of formula (VIII)
wherein R3 has the meaning indicated in claim 1,
and subsequently coupled with a benzothiophen-2-yl boronate of formula (VI)
wherein R1, R2 and R14 have the meanings indicated above,
in the presence of a palladium catalyst and a base to give a compound of formula (IX)
wherein R1, R2 and R3 have the meanings indicated in claim 1,
which then is either
[B-1] reacted with an amine of formula (III)
wherein R9 and R10 have the meanings indicated in claim 1,
in the presence of an acid and a reducing agent to yield the target compound of formula (I-A)
wherein R1, R2, R3, R9 and R10 have the meanings indicated in claim 1,
or
[B-2] oxidized to a carboxylic acid of formula (X)
wherein R1, R2 and R3 have the meanings indicated in claim,
and finally coupled with an amine of formula (XI)
wherein R11 and R12 have the meanings indicated in claim 1,
in the presence of a condensing agent to yield the target compound of formula (I-B)
wherein R1, R2, R3, R11 and R12 have the meanings indicated in claim 1,
or
[C] a 6-substituted 4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine of formula (XII)
is at first coupled with a benzothiophen-2-yl boronate of formula (VI)
wherein R1, R2 and R14 have the meanings indicated above,
in the presence of a palladium catalyst and a base to give a compound of formula (XIII)
wherein R1 and R2 have the meanings indicated in claim 1,
and then reacted with formaldehyde and an amine of formula (III)
wherein R9 and R10 have the meanings indicated in claim 1,
in the presence of an acid to yield the compound of formula (III)
wherein R1, R2, R9 and R10 have the meanings indicated in claim 1,
which subsequently is either
[C-1] oxidized to an aldehyde of formula (XIV)
wherein R1, R2, R9 and R10 have the meanings indicated in claim 1,
and treated with an amine of formula (XV)
wherein R4 and R5 have the meanings indicated in claim 1
in the presence of an acid and a reducing agent to yield the target compound of formula (I-D)
wherein R1, R2, R4, R5, R9 and R10 have the meanings indicated in claim 1,
or
[C-2] converted into the corresponding 6-(halomethyl) derivative of formula (XVI)
wherein R1, R2, R9 and R10 have the meanings indicated in claim 1,
and
X is chloro, bromo or iodo,
and treated with an alcohol of formula (XVII)
R3A—OH (XVII),
wherein R3A has the meaning of R3 as indicated in claim 1, except for hydrogen,
in the presence of a base to yield the target compound of formula (I-E)
wherein R1, R2, R3A, R9 and R10 have the meanings indicated above,
optionally followed by (i) separating the compound of formula (I) thus obtained into its enantiomers and/or diastereomers, and/or (ii) converting the compound of formula (I) into a hydrate, solvate, salt and/or hydrate or solvate of the salt by treatment with the corresponding solvents and/or acids or bases.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9 further comprising one or more additional therapeutic agents.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method for the treatment and/or prevention of cancer or tumor diseases in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of one or more compounds according to claim 1.
